Sutezolid

Sutezolid

Clinical data
Other names	PNU-100480, PF-02341272
Identifiers
IUPAC name N-[[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
CAS Number	168828-58-8
PubChem CID	465951
DrugBank	DB11905
ChemSpider	409595
UNII	3A71182L8P
KEGG	D10167
ChEMBL	ChEMBL288149
CompTox Dashboard (EPA)	DTXSID20168611
ECHA InfoCard	100.237.103
Chemical and physical data
Formula	C16H20FN3O3S
Molar mass	353.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCSCC3)F
InChI InChI=InChI=1S/C16H20FN3O3S/c1-11(21)18-9-13-10-20(16(22)23-13)12-2-3-15(14(17)8-12)19-4-6-24-7-5-19/h2-3,8,13H,4-7,9-10H2,1H3,(H,18,21)/t13-/m0/s1 Key:FNDDDNOJWPQCBZ-ZDUSSCGKSA-N

Sutezolid is an investigational new drug that is being evaluated for the treatment of extensively drug-resistant tuberculosis. It differs from linezolid by replacement of the morpholine oxygen with a sulfur atom. Like linezolid, sutezolid is a bacterial protein synthesis inhibitor. In preclinical studies, sutezolid demonstrated superior antituberculosis activity compared to linezolid.